Original Research
Estimated use of abacavir among adults and children enrolled in public sector antiretroviral therapy programmes in Gauteng, South Africa
Southern African Journal of HIV Medicine | Vol 13, No 3 | a126 |
DOI: https://doi.org/10.4102/sajhivmed.v13i3.126
| © 2012 Copyright Status: Not provided. Contact Holding Institution to verify copyright status. Rights Holder: Southern African HIV Clinicians Society
Submitted: 15 December 2012 | Published: 16 August 2012
Submitted: 15 December 2012 | Published: 16 August 2012
About the author(s)
D Evans, Health Economics and Epidemiology Research Office, Department of Medicine, University of the Witwatersrand, Johannesburg, South AfricaM Maskwe, Health Economics and Epidemiology Research Office, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa
C Heneger, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
I Sanne, Clinical HIV Research Unit, Department of Medicine, University of the Witwatersrand, and Right to Care, Johannesburg, South Africa
Abstract
In South Africa, abacavir (ABC) is currently recommended as part of first- and second-line antiretroviral therapy (ART) for HIV-positive paediatric patients. Concerns about overprescribing of the drug, particularly to adults, led to an analysis of ABC use in public sector ART programmes. We investigated current prescription of the drug to adults and children accessing ART in 4 public sector programmes across Gauteng Province, South Africa. ABC was almost exclusively prescribed to children initiating ART and adults requiring regimen changes due to drug toxicities. Patterns of ABC use among HIV-positive paediatric patients followed national ART treatment guidelines on the application of the drug. Although ABC is commonly used in the private sector for adults, the current national ART treatment guidelines for adults and adolescents should include ABC as an alternative to standard first- or second-line ART.
Keywords
HIV; ART; Abacavir; public sector;
Metrics
Total abstract views: 4695Total article views: 6219
Crossref Citations
1. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa
Dorina Onoya, Kamban Hirasen, Liudmyla van den Berg, Jacqui Miot, Lawrence C. Long, Matthew P. Fox
Drug Safety vol: 41 issue: 12 first page: 1343 year: 2018
doi: 10.1007/s40264-018-0698-3
2. Differentiated service delivery for people using second‐line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu‐Natal, South Africa
Lara Lewis, Yukteshwar Sookrajh, Kelly Gate, Thokozani Khubone, Munthra Maraj, Siyabonga Mkhize, Lucas E. Hermans, Hope Ngobese, Nigel Garrett, Jienchi Dorward
Journal of the International AIDS Society vol: 24 issue: S6 year: 2021
doi: 10.1002/jia2.25802

